Noxopharm Ltd
ASX:NOX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Atrium Ljungberg AB
F:A1A0
|
SE |
|
Devon Energy Corp
NYSE:DVN
|
US |
|
C
|
Calidi Biotherapeutics Inc
AMEX:CLDI
|
US |
Noxopharm Ltd
PP&E Net
Noxopharm Ltd
PP&E Net Peer Comparison
Noxopharm Ltd
Glance View
Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Gordon, New South Wales. The company went IPO on 2016-08-09. The firm is focused on the treatment of cancer and cytokine release syndrome or septic shock. The firm is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The firm's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The firm's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).
See Also
What is Noxopharm Ltd's PP&E Net?
PP&E Net
3.1k
AUD
Based on the financial report for Dec 31, 2025, Noxopharm Ltd's PP&E Net amounts to 3.1k AUD.
What is Noxopharm Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
-65%
Over the last year, the PP&E Net growth was -35%. The average annual PP&E Net growth rates for Noxopharm Ltd have been -45% over the past three years , -65% over the past five years .
